Refine
Document Type
- Article (51)
Language
- English (51)
Has Fulltext
- yes (51)
Is part of the Bibliography
- no (51)
Keywords
- cirrhosis (9)
- ACLF (8)
- Cirrhosis (7)
- portal hypertension (7)
- inflammation (5)
- liver cirrhosis (5)
- NASH (4)
- Portal hypertension (4)
- acute-on-chronic liver failure (4)
- NAFLD (3)
- Portal veins (3)
- acute decompensation (3)
- liver transplantation (3)
- macrophage (3)
- microbiome (3)
- Acute decompensation (2)
- Acute-on-chronic liver failure (2)
- Ascites (2)
- Liver diseases (2)
- Liver fibrosis (2)
- TIPS (2)
- Veins (2)
- angiogenesis (2)
- autophagy (2)
- extracellular matrix (2)
- fibrosis (2)
- hepatic encephalopathy (2)
- liver fibrosis (2)
- proteoglycan (2)
- steatosis (2)
- 16S rRNA sequencing (1)
- ADGRE1 (1)
- AKI (1)
- ALD (1)
- Aminotransferases (1)
- Angiogenesis (1)
- Angiography (1)
- Bacterial infection (1)
- Bilirubin (1)
- Biomarkers (1)
- Blood (1)
- Blood plasma (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- Circulating MiRNA (1)
- Clinical trials (1)
- Collagen (1)
- Collagens (1)
- EMR1 (1)
- Endpoints (1)
- Extracellular matrix (1)
- F4/80 (1)
- FXR (1)
- Fatty liver (1)
- Fibrosis (1)
- Gut-liver-axis (1)
- HIV (1)
- HSC (1)
- HVPG (1)
- Hepatic encephalopathy (1)
- Hepatic stellate cell (1)
- Hyponatremia (1)
- Immune Response (1)
- Immune paralysis (1)
- Infections (1)
- Interventional Trials (1)
- LSEC (1)
- Liver Fibrosis (1)
- Liver transplant (1)
- Liver-Related Complications (1)
- Mechanisms of disease (1)
- Metabolic dysfunction (1)
- Metalloproteinases (1)
- Methicillin-resistant Staphylococcus aureus (1)
- MiR-29 (1)
- Molecular medicine (1)
- NO (1)
- NSBB (1)
- Organ failure (1)
- PDE‐5‐inhibitor (1)
- Patients (1)
- Platelets (1)
- Prostaglandin (1)
- Quality of life (1)
- Rho-kinase (1)
- Roux-en-Y gastric bypass (1)
- SPSS (1)
- Splanchnic Hemodynamics (1)
- Steatosis (1)
- Surgery (1)
- Systemic inflammation (1)
- TGF-β1 (1)
- TGR(mREN2)27 (1)
- Thrombosis (1)
- Thromboxane (1)
- Toll-like receptor (1)
- Transjugular intrahepatic portosystemic shunt (1)
- VEGF (1)
- Western diet (1)
- White blood cells (1)
- acoustic radiation force impulse (1)
- acute decompensation of cirrhosis (1)
- acute-on-chronic liver failure (ACLF) (1)
- acute‐on‐chronic liver failure (1)
- alcoholic fatty liver disease (1)
- alcoholic hepatitis (1)
- animal model (1)
- antimicrobial stewardship (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- ascites (1)
- bacterial translocation (1)
- beta‐trace protein (1)
- biglycan (1)
- bile acids (1)
- biliary stricture (1)
- cancer (1)
- carbapenem resistance (1)
- caspase-1 (1)
- chronic hepatitis C (1)
- chronic liver disease (1)
- circulation (1)
- computed tomography (1)
- cystatin C (1)
- cytokines (1)
- death rates (1)
- decompensated liver cirrhosis (1)
- decorin (1)
- direct-acting antiviral (DAA) treatment (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- epidemiology (1)
- erectile dysfunction (1)
- fibromodulin (1)
- glycosaminoglycan (1)
- hemodynamic (1)
- hepatic stellate cells (1)
- hepatocellular cancer (1)
- hospital admission (1)
- immunity (1)
- in vitro models (1)
- infection control (1)
- inflammasome (1)
- intestinal manipulation (1)
- lipid droplets (1)
- lipidomics (1)
- lipoxin A4 (1)
- liver (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- lumican (1)
- male (1)
- mechanical ventilation (1)
- medical risk factors (1)
- metabolic liver disease (1)
- metabolomics (1)
- mini gastric bypass (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mortality (1)
- mouse (1)
- multidrug resistance (1)
- myeloid cells (1)
- non-alcoholic fatty liver disease (1)
- non‐selective beta‐blocker (1)
- one anastomosis gastric bypass (1)
- organ dysfunction (1)
- organ failure (1)
- pancreatic cancer (1)
- pancreatic surgery (1)
- portal pressure (1)
- portosystemic shunt (1)
- postoperative complications (1)
- pseudomonas aeruginosa (1)
- pulmonary failure (1)
- recurrent cholangitis (1)
- renal function (1)
- renin-angiotensin system (1)
- resolution of inflammation (1)
- respiratory failure (1)
- sCD163 (1)
- sCD206 (1)
- scavenger receptor (1)
- short-course antibiotic therapy (1)
- shunt (1)
- signature (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- spontaneous portosystemic shunt (1)
- statins (1)
- surgery (1)
- systemic inflammation (1)
- toll-like receptor (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- transjugular portosystemic intrahepatic (1)
- transmission (1)
- transplant-free survival (1)
- vasodilation (1)
- weight loss (1)
- whole-genome sequencing (1)
- fibrogenesis (1)
Institute
Argonaute 2 (AGO2) is an indispensable component of the RNA-induced silencing complex, operating at the translational or posttranscriptional level. It is compartmentalized into structures such as GW- and P-bodies, stress granules and adherens junctions as well as the midbody. Here we show using immunofluorescence, image and bioinformatic analysis and cytogenetics that AGO2 also resides in membrane protrusions such as open- and close-ended tubes. The latter are cytokinetic bridges where AGO2 colocalizes at the midbody arms with cytoskeletal components such as α-Τubulin and Aurora B, and various kinases. AGO2, phosphorylated on serine 387, is located together with Dicer at the midbody ring in a manner dependent on p38 MAPK activity. We further show that AGO2 is stress sensitive and important to ensure the proper chromosome segregation and cytokinetic fidelity. We suggest that AGO2 is part of a regulatory mechanism triggered by cytokinetic stress to generate the appropriate micro-environment for local transcript homeostasis.
The complex and adaptive nature of malignant neoplasm constitute a major challenge for the development of effective anti-oncogenic therapies. Emerging evidence has uncovered the pivotal functions exerted by the small leucine-rich proteoglycans, decorin and biglycan, in affecting tumor growth and progression. In their soluble forms, decorin and biglycan act as powerful signaling molecules. By receptor-mediated signal transduction, both proteoglycans modulate key processes vital for tumor initiation and progression, such as autophagy, inflammation, cell-cycle, apoptosis, and angiogenesis. Despite of their structural homology, these two proteoglycans interact with distinct cell surface receptors and thus modulate distinct signaling pathways that ultimately affect cancer development. In this review, we summarize growing evidence for the complex roles of decorin and biglycan signaling in tumor biology and address potential novel therapeutic implications.
Background & Aims: Acute-on-chronic liver failure (ACLF) is a syndrome associated with organ failure and high short-term mortality. Recently, the role of surgery as a precipitating event for ACLF has been characterised. However, the impact of preoperative transjugular intrahepatic portosystemic shunt (TIPS) placement on ACLF development in patients with cirrhosis undergoing surgery has not been investigated yet.
Methods: A total of 926 patients (363 with cirrhosis undergoing surgery and 563 patients with TIPS) were screened. Forty-five patients with preoperative TIPS (TIPS group) were 1:1 propensity matched to patients without preoperative TIPS (no-TIPS group). The primary endpoint was the development of ACLF within 28 and 90 days after surgery. The secondary endpoint was 1-year mortality. Results were confirmed by a differently 1:2 matched cohort (n = 176).
Results: Patients in the no-TIPS group had significantly higher rates of ACLF within 28 days (29 vs. 9%; p = 0.016) and 90 days (33 vs. 13%; p = 0.020) after surgery as well as significantly higher 1-year mortality (38 vs. 18%; p = 0.023) compared with those in the TIPS group. Surgery without preoperative TIPS and Chronic Liver Failure Consortium–Acute Decompensation (CLIF-C AD) score were independent predictors for 28- and 90-day ACLF development and 1-year mortality after surgery, especially in patients undergoing visceral surgery. In the no-TIPS group, a CLIF-C AD score of >45 could be identified as cut-off for patients at risk for postoperative ACLF development benefiting from TIPS.
Conclusions: This study suggests that preoperative TIPS may result in lower rates of postoperative ACLF development especially in patients undergoing visceral surgery and with a CLIF-C AD score above 45.
Lay summary: Acute-on-chronic liver failure (ACLF) is a syndrome that is associated with high short-term mortality. Surgical procedures are a known precipitating event for ACLF. This study investigates the role of preoperative insertion of a transjugular intrahepatic portosystemic shunt (TIPS) on postoperative mortality and ACLF development. Patients with TIPS insertion before a surgical procedure exhibit improved postoperative survival and lower rates of postoperative ACLF, especially in patients undergoing visceral surgery and with a high CLIF-C AD prognostic score. Thus, this study suggests preoperative TIPS insertion in those high-risk patients.
Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are the leading causes of liver disease worldwide. To identify disease-specific pathomechanisms, we analyzed the lipidome, metabolome and immune cell recruitment in livers in both diseases. Mice harboring ASH or NASH had comparable disease severities regarding mortality rate, neurological behavior, expression of fibrosis marker and albumin levels. Lipid droplet size was higher in NASH than ASH and qualitative differences in the lipidome were mainly based on incorporation of diet-specific fatty acids into triglycerides, phosphatidylcholines and lysophosphatidylcholines. Metabolomic analysis showed downregulated nucleoside levels in both models. Here, the corresponding uremic metabolites were only upregulated in NASH suggesting stronger cellular senescence, which was supported by lower antioxidant levels in NASH as compared to ASH. While altered urea cycle metabolites suggest increased nitric oxide synthesis in both models, in ASH, this depended on increased L-homoarginine levels indicating a cardiovascular response mechanism. Interestingly, only in NASH were the levels of tryptophan and its anti-inflammatory metabolite kynurenine upregulated. Fittingly, high-content immunohistochemistry showed a decreased macrophage recruitment and an increased polarization towards M2-like macrophages in NASH. In conclusion, with comparable disease severity in both models, higher lipid storage, oxidative stress and tryptophan/kynurenine levels were seen in NASH, leading to distinct immune responses.
Purpose of the Review: This review aims to summarize the current knowledge of the extracellular matrix remodeling during hepatic fibrosis. We discuss the diverse interactions of the extracellular matrix with hepatic cells and the surrounding matrix in liver fibrosis, with the focus on the molecular pathways and the mechanisms that regulate extracellular matrix remodeling.
Recent Findings: The extracellular matrix not only provides structure and support for the cells, but also controls cell behavior by providing adhesion signals and by acting as a reservoir of growth factors and cytokines.
Summary: Hepatic fibrosis is characterized by an excessive accumulation of extracellular matrix. During fibrogenesis, the natural remodeling process of the extracellular matrix varies, resulting in the excessive accumulation of its components, mainly collagens. Signals released by the extracellular matrix induce the activation of hepatic stellate cells, which are the major source of extracellular matrix and most abundant myofibroblasts in the liver.
Background: Cirrhosis is known to have a high prevalence and mortality worldwide. However, in Europe, the epidemiology of cirrhosis is possibly undergoing demographic changes, and etiologies may have changed due to improvements in standard of care. The aim of this population-based study was to analyze the trends and the course of liver cirrhosis and its complications in recent years in Germany.
Methods: We analyzed the data of all hospital admissions in Germany within diagnosis-related groups from 2005 to 2018. The diagnostic records of cirrhosis and other categories of diseases were based on ICD-10-GM codes. The primary outcome measurement was in-hospital mortality. Trends were analyzed through Poisson regression of annual number of admissions. The impact of cirrhosis on overall in-hospital mortality were assessed through the multivariate multilevel logistic regression model adjusted for age, sex, and comorbidities.
Findings: Of the 248,085,936 admissions recorded between 2005 and 2018, a total of 2,302,171(0•94%) were admitted with the diagnosis of cirrhosis, mainly as a comorbidity. Compared with other chronic diseases, patients admitted with cirrhosis were younger, mainly male and had the highest in-hospital mortality rate. Diagnosis of cirrhosis was an independent risk factor of in-hospital mortality with the highest odds ratio (OR:6•2[95%CI:6.1-6•3]) among all diagnoses. The prevalence of non-alcoholic fatty liver disease has increased four times from 2005 to 2018, while alcoholic cirrhosis is 20 times than other etiologies. Bleeding was found to be decreasing over time, but ascites remained the most common complication and was increasing.
Interpretation: This nationwide study demonstrates that cirrhosis represents a considerable healthcare burden, as shown by the increasing in-hospital mortality, also in combination with other chronic diseases. Alcohol-related cirrhosis and complications are on the rise. More resources and better management strategies are warranted.
Objectives: Stenosis of the biliary anastomosis predisposes liver graft recipients to bacterial cholangitis. Antibiotic therapy (AT) is performed according to individual clinical judgment, but duration of AT remains unclear.
Methods: All liver graft recipients with acute cholangitis according to the Tokyo criteria grade 1 and 2 after endoscopic retrograde cholangiography (ERC) were included. Outcome of patients treated with short AT (<7 days) was compared to long AT (>6 days). Recurrent cholangitis (RC) within 28 days was the primary end point.
Results: In total, 30 patients were included with a median of 313 (range 34–9849) days after liver transplantation until first proven cholangitis. Among 62 cases in total, 51/62 (82%) were graded as Tokyo-1 and 11/62 (18%) as Tokyo-2. Overall median duration of AT was 6 days (1–14) with 36 cases (58%) receiving short AT and 26 (42%) receiving long AT. RC was observed in 10 (16%) cases, without significant difference in occurrence of RC in short versus long AT cases. CRP and bilirubin were significantly higher in patients with long AT, while low serum albumin and low platelets were associated with risk of RC.
Conclusion: A shorter antibiotic course than 7 days shows good results in selected, ERC-treated patients for post-transplantation biliary strictures.
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.